H.I.G. Capital Announces the Sale of Celerion

MIAMI, April 22, 2026 /PRNewswire/ -- H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $74 billion of capital under management, is pleased to announce that one of its affiliates has signed a definitive agreement to sell its portfolio company, Celerion Holdings, Inc. ("Celerion" or the "Company"), a global CRO and leader in clinical pharmacology and bioanalytical sciences, to funds affiliated with THL Partners ("THL").

Headquartered in Lincoln, Nebraska, Celerion is a leading provider of highly specialized clinical pharmacology and bioanalytical sciences with deep expertise in first-in-human dose escalation, cardiac safety (TQT), drug-drug interaction, and other complex clinical pharmacology studies that support regulatory approval and drug labeling. Celerion offers an integrated suite of services spanning data management, biostatistics, and clinical monitoring that supports a global base of pharmaceutical and biotechnology customers through its purpose-built clinical and laboratory infrastructure with facilities in Lincoln, Phoenix, Zurich, and Belfast.

H.I.G. acquired Celerion in November 2022 and worked closely with management to accelerate growth and strengthen the Company's market position. During its ownership, H.I.G. supported strategic investments across commercial, operational, and technology initiatives, including the expansion of Celerion's clinical and bioanalytical laboratory footprint. These efforts drove exceptional growth and solidified Celerion's standing as a leading, clinical pharmacology-focused, contract research organization.

Susan Thornton, Celerion's President & CEO, commented, "H.I.G. has been an exceptional partner to Celerion, helping us accelerate key strategic initiatives and invest meaningfully in our people, capabilities, and infrastructure. These efforts have strengthened our platform and enhanced the quality and consistency of outcomes we deliver to customers. We are excited to carry this momentum forward with THL as we enter our next phase of growth."

Mike Gallagher, Managing Director at H.I.G., commented, "We are proud of what Celerion's best-in-class team has accomplished during our partnership. The team has delivered industry- leading growth during our ownership, and we are confident it is uniquely positioned for its next chapter."

Michael Kuritzky, Managing Director at H.I.G., added, "We are very proud of the work Celerion does to help drug sponsors worldwide navigate the complexities of clinical trial management. It has been a privilege to partner with Susan and her team, and we look forward to Celerion's continued success."

BofA Securities, Inc. and Lazard Frères & Co. LLC were financial advisors to H.I.G. and Celerion. McDermott Will & Schulte LLP was legal counsel for H.I.G. and Celerion in connection with the transaction.

About Celerion

Celerion is a clinical research organization that provides comprehensive clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research throughout North America, Europe, and Asia. The Company serves its clients through a global network of facilities and provides first-in-human to proof-of-concept studies as well as bioanalytical laboratory services, data management and biometrics, and drug development services. For more information, visit celerion.com.

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $74 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach:

• H.I.G.'s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
• H.I.G.'s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
• H.I.G.'s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
• H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm's current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and its affiliates.

Contact:

Mike Gallagher
Managing Director
[email protected]

Michael Kuritzky
Managing Director
[email protected]

Alex Zisson
Managing Director
[email protected]

H.I.G. Capital
1450 Brickell Avenue
31^st Floor
Miami, FL 33131
P: 305.379.2322
hig.com

SOURCE H.I.G. Capital